The clinical significance and management of lesion motion due to respiration during PET/CT scanning

Cancer Imaging

Volumn 11, Issue 1, 2011, Pages 224-236

  Callahan, Jason ^a   Kron, Tomas ^a   Schneider Kolsky, Michal ^b   Hicksa, Rodney J ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

4D PET CT; Clinical significance; Lesion motion; Respiratory gated PET

Indexed keywords

ARTIFACT; BREATHING; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; MONITORING; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; WHOLE BODY IMAGING;

ARTIFACTS; HUMANS; LUNG NEOPLASMS; MOVEMENT; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RESPIRATION; THERAPY, COMPUTER-ASSISTED;

EID: 84855445117     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2011.0031     Document Type: Review

References (32)

1. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005; 11: 7967-85. doi:10.1158/1078-0432.CCR-05-1302. (Pubitemid 41698738)
2. Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42: 1596-604. (Pubitemid 33131317)
3. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82. doi:10.1016/S0959-8049(99)00229-4. (Pubitemid 29512308)
4. Lupi A, Zaroccolo M, Salgarello M, Malfatti V, Zanco P. The effect of 18F-FDG-PET/CT respiratory gating on detected metabolic activity in lung lesions. Ann Nucl Med 2009; 23: 191-6. doi:10.1007/s12149-008-0225-1.
5. Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med 2008; 38: 167-76. doi:10.1053/j.semnuclmed.2008.01.002. (Pubitemid 351466915)
6. Nehmeh SA, Erdi YE, Ling CC, et al. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med 2002; 43: 876-81. (Pubitemid 34747809)
7. Nehmeh SA, Erdi YE, Pevsner A, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 2004; 31: 3179-86. doi:10.1118/1.1809778. (Pubitemid 40064969)
8. Park SJ, Ionascu D, Killoran J, et al. Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images. Phys Med Biol 2008; 53: 3661-79. doi:10.1088/0031-9155/53/13/018. (Pubitemid 352020047)
9. Wolthaus JW, van Herk M, Muller SH, et al. Fusion of respiration- correlated PET and CT scans: correlated lung tumour motion in anatomical and functional scans. Phys Med Biol 2005; 50: 1569-83. doi:10.1088/0031-9155/50/7/ 017. (Pubitemid 40524545)
10. Werner MK, Parker JA, Kolodny GM, English JR, Palmer MR. Respiratory gating enhances imaging of pulmonary nodules and measurement of tracer uptake in FDG PET/CT. AJR Am J Roentgenol 2009; 193: 1640-5. doi:10.2214/AJR.09.2516.
11. Garcia Vicente AM, Soriano Castrej-on AM, Talavera Rubio MP, et al. (18)F-FDG PET-CT respiratory gating in characterization of pulmonary lesions: approximation towards clinical indications. Ann Nucl Med 2010; 24: 207-14. doi:10.1007/s12149-010-0345-2.
12. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med 1996; 21: 941-9. doi:10.1097/00003072-199612000-00005. (Pubitemid 26412217)
13. Larson SM, Nehmeh SA, Erdi YE, Humm JL. PET/CT in non-small-cell lung cancer: value of respiratory-gated PET. Chang Gung Med J 2005; 28: 306-14. (Pubitemid 41020838)
14. Liu C, Pierce LA, II. Alessio AM, Kinahan PE. The impact of respiratory motion on tumor quantification and delineation in static PET/CT imaging. Phys Med Biol 2009; 54: 7345-62. doi:10.1088/0031-9155/54/24/007.
15. MacManus M, Hicks RJ, Everitt S. Role of PET-CT in the optimization of thoracic radiotherapy. J Thorac Oncol 2006; 1: 81-4. doi:10.1097/01243894- 200601000-00017. (Pubitemid 47164027)
16. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009; 91: 85-94. doi:10.1016/j.radonc.2008.11.008.
17. MacManus MP. Use of PET/CT for staging and radiation therapy planning in patients with non-small cell lung cancer. Q J Nucl Med Mol Imaging 2010; 54: 510-20.
18. Aristophanous M, Berbeco RI, Killoran JH, et al. Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. Int J Radiat Oncol Biol Phys 2011. [Epub ahead of print].
19. Nath SK, Sandhu AP, Jensen L, et al. Frameless image-guided stereotactic body radiation therapy for lung tumors with 4-dimensional computed tomography or 4-dimensional positron emission tomography/computed tomography. Clin Lung Cancer 2011; 12: 180-6. doi:10.1016/j.cllc.2011.03.014.
20. Purdie TG, Moseley DJ, Bissonnette JP, et al. Respiration correlated cone-beam computed tomography and 4DCT for evaluating target motion in Stereotactic Lung Radiation Therapy. Acta Oncol 2006; 45: 915-22. doi:10.1080/02841860600907345. (Pubitemid 44423140)
21. Slotman BJ, Lagerwaard FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. Acta Oncol 2006; 45: 966-72. doi:10.1080/02841860600902817. (Pubitemid 44423147)
22. Stoelben E, Ludwig C. Chest wall resection for lung cancer: indications and techniques. Eur J Cardiothorac Surg 2009; 35: 450-6. doi:10.1016/j.ejcts. 2008.11.032.
23. Mileshkin L, Hicks RJ, Hughes BG, et al. Changes in 18F- fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011; 17: 3304-15. doi:10.1158/1078-0432.CCR-10-2763.
24. Zhang HQ, Yu JM, Meng X, Yue JB, Feng R, Ma L. Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy. Eur J Radiol 2011; 77: 92-6. doi:10.1016/j.ejrad.2009.07.023.
25. Reinhardt MJ, Wiethoelter N, Matthies A, et al. PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation- corrected and non-attenuation-corrected PET images. Eur J Nucl Med Mol Imaging 2006; 33: 134-9. doi:10.1007/s00259-005-1901-1. (Pubitemid 43152879)
26. Hanley J, Debois MM, Mah D, et al. Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation. Int J Radiat Oncol Biol Phys 1999; 45: 603-11. (Pubitemid 29462639)
27. Rosenzweig KE, Hanley J, Mah D, et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000; 48: 81-7. doi:10.1016/S0360-3016(00)00583-6. (Pubitemid 30488216)
28. Nehmeh SA, Erdi YE, Meirelles GS, et al. Deep-inspiration breath-hold PET/CT of the thorax. J Nucl Med 2007; 48: 22-6. (Pubitemid 47555370)
29. Fin L, Daouk J, Morvan J, et al. Initial clinical results for breathhold CT-based processing of respiratory-gated PET acquisitions. Eur J Nucl Med Mol Imaging 2008; 3: 1971-80.
30. Pan T, Mawlawi O, Nehmeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 2005; 46: 1481-7. (Pubitemid 46173260)
31. Erdi YE, Nehmeh SA, Pan T, et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med 2004; 45: 1287-92. (Pubitemid 47618524)
32. Otani Y, Fukuda I, Tsukamoto N, et al. A comparison of the respiratory signals acquired by different respiratory monitoring systems used in respiratory gated radiotherapy. Med Phys 2010; 37: 6178-86. doi:10.1118/1.3512798.